Natasha Bigsby, Principal, has been synthesizing data to curate sustainable growth opportunities for over 19 years, 12 of which have been with FORTUNE® 150 companies.  

​

Natasha began her career with Wells Fargo Financial, underwriting loans and developing business.  After earning an MBA, Natasha joined Eli Lilly as a marketer in its U.S. Oncology business unit, with a focus on sales force effectiveness and marketing/sales alignment.  Beyond triangulating data to influence key strategic decisions and foster sales force quota attainment, Natasha developed processes that resulted in enhanced customer message recall, and was instrumental in initiating a Lilly Oncology competitive intelligence network.

​

After completing a short-term sales assignment in Lilly’s Diabetes Care division with top 20% portfolio performance, Natasha transitioned to an upstream diabetes marketing role. As part of a lean team, Natasha not only led market analysis, but also spearheaded both HCP and payer KOL identification/engagement, leveraging insights gleaned from each to shape the global commercialization strategy and corresponding phase 2/3 clinical trial plan.  Additionally, Natasha was integral in implementing initiatives that separately reinforced product differentiation across pre-approval touchpoints and mitigated competitor intelligence gathering.  Natasha earned a Global Brand Development Quality award and a Marketing EXCEL Innovation award for her contributions to the team, while also successfully completing Lean Six Sigma Green Belt training.

​

Presented with an opportunity to lead brand planning for the largest customer segment of a blockbuster drug with numerous indications, Natasha joined Lilly’s U.S. Neuroscience business unit. In addition to developing a strategic construct to optimize growth across all U.S. indications, Natasha was also instrumental in creating a shared vision for how to effectively compete within a new therapeutic area. Most significant, however, was Natasha’s achieving all success metrics as launch leader for a new formulation of the brand’s most prescribed dosage strength, valued at ~$1.25 billion.

​

Passionate about helping organizations become more successful and competitive, after contributing to team wins across biologics and small-molecules, Natasha founded Strategic Relevance.  A pivot from corporate, in recognition that the travel-intensive, dual-career family scenario was less than ideal with two young sons, Natasha has enjoyed meaningfully impacting strategic decisions across therapeutic areas. “Strategic Relevance” was inspired by a physician quip on House MD: “Philosophically interesting, medically irrelevant”.  Equally amused by and smitten with the remark, for years, it has served as a good reminder to stay focused on what will make a difference.  Natasha finds it gratifying that each client has engaged Strategic Relevance in more than one project—a true testament to the value added.